Promising Data For CF Drug Published in The Lancet
| 1 min read

Positive data for PTC124, one of the first potential therapies to address the basic defect in CF were published today in The Lancet. The Phase 2 data show that treatment with PTC124 improves the function of the faulty CFTR protein in patients with a specific type of CF mutation known as nonsense-mutation. The Lancet is one of the oldest peer-reviewed medical journals in the world.

Share this article
Topics
About the CF Foundation | CFTR Modulators | Genetic Therapies
Recent news
CF Foundation Reflects on Progress Toward Equity, Racial Justice, Diversity, and Inclusion
News | 4 min read
CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method
News | 2 min read
CF Foundation Urges Vertex Pharmaceuticals to Reverse Consequential Decision on Copay Assistance
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe